The global viral clearance market is expected to witness significant growth over the forecast period. Viruses are microscopic organisms that are contagious agents that reproduce only inside the living cells of other organisms. Viruses can infect all types of life forms right from a bacterium to archaea and also animals and plants to microorganisms. Viruses are not alive. They do not have the ability to grow or multiply on their own and require to go into an animal or human cell and multiply with the help of the host organism they live enter in. Viruses also have the ability to infect bacterial cells.
The mechanism used by viruses is that the virions that are the virus particles attack the cell and capture the machinery to bring out their multiplication and growth. The infected cell then produces viral particles instead of their regular products.
The evaluation of the virology safety of a product and the capability of an engineering process to form a product which is harmless and risk-free for human use is a fundamental measure during the development of a biological product. To achieve these criteria, there is a need to perform viral safety assays and subsequently to conduct viral clearance in the course of product development.
The factors that propel the growth of the global viral clearance market include a strong pharmaceutical product pipeline that will benefit in the development of the pharmaceutical and biotechnology industry, the rising government funding for the pharmaceutical and biotechnology industries, the innovation of novel drugs, and rise in R&D activities. Additionally, the increased emphasis on quality assurance and quality control departments in the industries boost the growth of the global market.
On the other hand, there are also factors that hamper the growth of the global viral clearance market like the high degree of consolidation act.
The global viral clearance market is classified on the basis of application, method, end-users and geography.
On the basis of application, the global market is classified as blood & blood products, cellular & gene therapy products, Tissue & Tissue Products, vaccines and therapeutics, and stem cell products. Amongst the application sector, the Vaccines and Therapeutics account for the highest share of the global market.
On the basis of the method, the global market is classified as a viral detection method, viral inactivation method, and viral removal method. In 2015, the viral detection method holds for the major share of the global market.
On the basis of end-users, the global market is classified as Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Other End Users. The other end-users consist of medical device companies, microbiology laboratories, immunology laboratories, molecular laboratories, animal facilities, toxicology laboratories, cell banks, small cell culture laboratories and consultants, and media/sera manufacturers.
On the basis of geography, the global viral clearance market is classified as North America, Europe, Asia, and the Rest of the World. North America sector is further sub-classified into U.S. and Canada.
Some of the prominent players that fuel the growth of the global market include Charles River Laboratories International, Inc., Lonza Group, Merck KGaA, Sigma-Aldrich Corporation, Avance Biosciences Inc., BSL BIOSERVICE, Clean Cells, SGS S.A., Texcell, Inc., and WuXi PharmaTech Inc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.